Form 4: Director Steve Krognes Exercises Guardant Health RSUs

Director Steve Krognes acquired 154 shares of Guardant Health common stock through the vesting of restricted stock units.

Summary

• Director Steve Krognes acquired 154 shares of Guardant Health (GH) common stock on April 30, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs) granted on August 9, 2022.
• Following this transaction, the director holds a total of 19,362 shares of common stock.
• The transaction was executed at a price of $0 per share as part of a standard equity compensation vesting schedule.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative vesting of equity compensation rather than a market-driven buy or sell order.

Positives

• Director maintains a direct ownership stake of 19,362 shares, aligning interests with shareholders.

Negatives

• None identified; this is a routine equity compensation event.

Risks

• None identified; this is a routine equity compensation event.

Future Outlook

Not applicable; this is a historical record of an equity transaction.

Industry Context

StockSavvy.ai notes that routine RSU vesting for directors is standard corporate practice in the biotechnology and diagnostics sector, reflecting established compensation structures rather than discretionary market activity.

Comparison to Industry Standards

• The transaction follows standard industry practices for director compensation in publicly traded life sciences companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a pre-planned equity compensation event.

Next Steps

• Continued monthly vesting of the remaining RSU balance as per the original 2022 grant agreement.

Key Dates

Keywords

Guardant Health, GH, Form 4, Insider Trading, Equity Compensation, Steve Krognes